Please select the eligibility criteria that correspond to the clinical trial below.
Title: Follow up After Self-poisoning by General Practitioner- a Randomised Clinical Trial
Brief Summary: The study hypothesis is that follow up from general practitioner after hospitalization for self poisoning will decrease suicidal behaviour.


Options:
A: Inclusion Criteria:

* Adults with a high level of impulsivity (with or without ADHD) based on a CGI-S-score ≥ 4.
* An Affective Reactivity Index (ARI) score ≥5 indicating a high level of multi dimensional impulsivity.
* Research diagnosis of attention-deficit/hyperactivity disorder (ADHD) and/or borderline personality disorder (BPD) confirmed by structured diagnostic interview according to DSM-5 (ADHD: Diagnostic Interview for Adult ADHD (DIVA 2.0); BPD: Structured Clinical Interview for DSM-IV (SCID-II)).
* Not currently taking any antibiotics or probiotics.
* Deemed reliable and compliant with the protocol by the investigator.
* Ability to speak and comprehend the native language of the country in which the assessments take place.

Exclusion Criteria:

* Subject is being treated with a concomitant medication which is prohibited within this study according to the list of prohibited medications.
* Patients must be on stable medication (i.e. current dose is given since more than 30 days): up-titration is not allowed and careful clinical screening is done at all visits to check whether lower dosage is needed due to increased side effects as a result of treatment with Synbiotic2000Forte.
* Presence of major psychiatric disorders with psychotic's symptoms.
* Neurological disorder involving brain or other central function (e.g., intellectual disability with an assessed IQ \< 70, epilepsy, MS, narcolepsy) or other major psychiatric condition requiring hospitalization (e.g., significant mood disorder or psychosis).
* Major physical illness of the cardiovascular, endocrine, pulmonal, or the gastrointestinal system.
* History of or present clinically relevant somatic acute or chronic disorder that, in the opinion of the investigator, might confound the results of tolerability/safety assessment, or prohibit the patients from completing the study, or would not be in the best interest of the patient.
* Subject has a documented allergy, hypersensitivity, or intolerance to any of the ingredients of the intervention.
* Subject has taken another investigational product or taken part in a clinical study within 30 days prior to entering the study.
B: Inclusion Criteria:

* Patients with personality disorders admitted to Department for personality psychiatry, Psychiatric division, Ullevål University Hospital

Exclusion Criteria:

* Schizotypal personality disorder, antisocial personaliy disorder, current alcohol or drug dependence, developmental disorders (e.g. Asperger), symptoms due to organic conditions, and lack of a permanent residence.
C: Inclusion Criteria:

* age ≥ 18 years
* DSM-IV-TR diagnoses of BPD and PTSD
* legal competence
* none or stable medication
* illegal drug abstinence for at least the last 6 months
* capacity to consent and contract

Exclusion Criteria:

* other severe mental disorders (e.g., bipolar disorder, acute psychosis)
* simultaneous consumption of drugs
* simultaneous participation in other treatment-studies
* pregnancy or breastfeeding
* lack of capability to negotiate a no-suicide agreement
* suicide attempt or attempts during the 8 weeks prior to start of treatment
* perpetrator-contact
* Body Mass Index (BMI) \< 16
D: Inclusion Criteria:

* Self Poisoning (according to the WHO definition)
* Ability to fill out questionnaire

Exclusion Criteria:

* Hospitalization into psychiatric ward
* Unknown address or ID
* Not registered with General Practitioner
* If institutionalized or in jail.

Answer: D